MYGN

Myriad Genetics Inc. 10-Q Summary: Period Ended December 31, 2000

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Myriad Genetics, Inc., covering the three and six months ended December 31, 2000. The company operates in the fields of proteomics and gene-based medicine, focusing on two primary segments: Research (gene discovery, database subscriptions, and therapeutic development) and Predictive Medicine (genetic testing for disease predisposition). As of December 31, 2000, the company had an accumulated deficit of $55.9 million and had not yet attained profitability.

Key Financial Metrics

Revenue Breakdown (6 Months): Research revenue was $15.76 million; Predictive medicine revenue was $7.02 million.

Expense Breakdown (6 Months): Research and development expenses were $18.14 million; Selling, general, and administrative expenses were $8.02 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 45% for the six months ended Dec 31, 2000, compared to the prior year. Research revenue grew 37% due to new collaborations (Hoffmann-LaRoche, Hitachi, Syngenta). Predictive medicine revenue surged 93% driven by increased testing volume and wider medical acceptance.
• Expense Increases: R&D expenses rose 51% year-over-year due to expanded drug discovery efforts. SG&A expenses increased 26% to support business expansion and the launch of the COLARIS test.
• Liquidity Position: Cash, cash equivalents, and marketable securities increased by approximately $80.2 million (134%) from the prior year-end. This was primarily driven by a private stock sale raising approximately $87 million and advance payments from collaborators.
• Operating Cash Flow: Operating cash flow shifted from a positive $11.5 million in the prior six-month period to a negative $8.4 million, largely due to a $6.7 million decrease in deferred revenue as collaboration payments were recognized as revenue.

Guidance, Outlook, and Risks

Outlook: Management expects to incur losses for at least the next several years due to the expansion of R&D, drug discovery, staffing, and facilities. The company anticipates existing capital resources will be adequate for at least the next two years but intends to raise additional funds when market conditions are favorable.

Recent Developments:

• Acquired exclusive rights to develop MPC-7869 (a cancer drug) from Encore Pharmaceuticals, including a $2.7 million equity investment.
• Completed DNA sequencing of the rice genome for Syngenta, triggering a $3 million cash bonus (subsequent event).
• Launched COLARIS, a predictive test for hereditary colon and uterine cancer.

Risks and Contingencies:

• Profitability: No assurance of future profitability; dependent on successful commercialization of therapeutic products and predictive tests.
• Competition: Intense competition in gene discovery and genetic testing markets.
• Regulatory and Reimbursement: Uncertainty regarding government regulation and reimbursement from insurers for genetic tests.
• Collaboration Dependence: Significant reliance on collaborative agreements for funding and future royalties.

Key Facts for Investor Verification

• Capital Raise: Verify the terms and registration status of the $87 million private stock placement completed in August and October 2000.
• Deferred Revenue: Monitor the $12.76 million deferred revenue balance and the rate at which collaboration milestones are recognized as revenue.
• Encore Investment: Assess the progress and future milestone obligations related to the $2.7 million investment in Encore Pharmaceuticals for the MPC-7869 drug.
• Reimbursement Trends: Track reimbursement rates and acceptance of predictive medicine tests (BRACAnalysis, CardiaRisk, COLARIS) by third-party payors.
• Burn Rate: Evaluate the sustainability of the current operating cash burn ($8.4M over six months) against the $92.4M cash balance.